Malarial Vaccines Utilizing Antigen/Adjuvant Display on Viral-Like Particles

Award Information
Agency:
Department of Defense
Branch
n/a
Amount:
$629,510.00
Award Year:
2011
Program:
SBIR
Phase:
Phase II
Contract:
W81XWH-10-C-0005
Agency Tracking Number:
A2-4234
Solicitation Year:
2009
Solicitation Topic Code:
A09-107
Solicitation Number:
2009.2
Small Business Information
Agave BioSystems, Inc.
P.O. Box 100, Ithaca, NY, -
Hubzone Owned:
Y
Minority Owned:
Y
Woman Owned:
N
Duns:
022552900
Principal Investigator:
Mehran Pazirandeh
Staff Scientist
(607) 272-0002
mehranp@agavebio.com
Business Contact:
Noe Salazar
President
(512) 373-8601
nsalazar@agavebio.com
Research Institution:
Stub




Abstract
Recent studies have suggested the potential of improved malarial vaccines by use of the viral-like particle (VLP)-linked immunogen approach. The VLP technology is being utilized for the development of vaccines for a variety of diseases. Agave BioSystems is creating a novel platform for development of malarial vaccines consisting of a VLP displayed malarial antigen/adjuvant based on the Norwalk virus (NV) capsid protein. The VLP will be engineered to express a candidate antigen in combination with a peptide adjuvant. These VLPs will be characterized, purified and delivered for testing of efficacy to stimulate cellular and humoral immune responses.In the Phase I, Agave BioSystems successfully demonstrated proof-of concept for this novel platform.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government